Kenichi Hata
Overview
Explore the profile of Kenichi Hata including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
107
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hata K, Hashimoto M, Takahashi Y, Saito S, Kawaharada A, Enei Y, et al.
Nihon Hinyokika Gakkai Zasshi
. 2025 Jan;
115(1):11-20.
PMID: 39828343
(Objective) This study aimed at evaluating the efficacy and safety of upfront docetaxel (DTX) treatment and androgen deprivation therapy (ADT) in male patients with high-volume metastatic castration-sensitive prostate cancer (HV-mCSPC)....
2.
Fujimori K, Ishii K, Kyozuka H, Yasuda S, Murata T, Goto A, et al.
Fukushima J Med Sci
. 2024 Dec;
71(1):35-46.
PMID: 39694498
This study aimed to assess long-term changes in pregnancy and birth outcomes after the Great East Japan Earthquake and the accident at the Tokyo Electric Power Company's Fukushima Daiichi Nuclear...
3.
Hara S, Urabe F, Tashiro K, Goto Y, Iwamoto Y, Ohtsuka T, et al.
Jpn J Clin Oncol
. 2024 Oct;
55(2):158-163.
PMID: 39426804
Objective: We determined the optimal timing for initiating androgen receptor signaling inhibitor (ARSI) therapy in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) and assessed its impact on oncological outcomes. Materials...
4.
Narita S, Yanagisawa T, Hatakeyama S, Hata K, Fujita K, Ueda T, et al.
Prostate
. 2024 Sep;
85(1):73-81.
PMID: 39344365
Background: To develop and validate a prognostic risk model for high-risk metastatic hormone-sensitive prostate cancer (mHSPC) patients treated with upfront abiraterone acetate (ABI). Methods: This retrospective multicenter study involved 233...
5.
Hata K, Kato J, Takahashi Y, Saito S, Sakanaka K, Kimura T
Case Rep Urol
. 2024 Aug;
2024:2760153.
PMID: 39161780
Acquired hemophilia A (AHA) is an acquired bleeding disorder caused by neutralizing antibodies (inhibitors) against Coagulation Factor VIII (FVIII:C), causing sudden hemorrhagic symptoms (i.e., subcutaneous bleeding, intramuscular bleeding, and hematuria)....
6.
Urabe F, Imai Y, Goto Y, Tashiro K, Hashimoto M, Yoshihara K, et al.
Jpn J Clin Oncol
. 2024 Jul;
54(11):1208-1213.
PMID: 39037966
Background: Two randomized trials demonstrated that the survival benefits afforded by triplet therapy were greater than those of doublet therapy, thus changing the treatment paradigm for metastatic castration-sensitive prostate cancer...
7.
Shimomura T, Mori K, Ito K, Yasue K, Matsukawa A, Fukuokaya W, et al.
Int Urol Nephrol
. 2024 Jun;
56(12):3719-3725.
PMID: 38913290
Purpose: Although docetaxel and ARSI are picked up as treatment options against chemo-naïve metastatic CRPC in clinical guidelines for prostate cancer, there is no clear evidence which agent should be...
8.
Tashiro K, Kimura S, Tsuzuki S, Urabe F, Fukuokaya W, Mori K, et al.
Clin Genitourin Cancer
. 2024 Apr;
22(3):102075.
PMID: 38643665
Background: The critical role of radiographic assessment at the time of castration-resistant prostate cancer (CRPC) diagnosis is underscored by this study. We performed a retrospective analysis of radiographic changes in...
9.
Kayano S, Yanagisawa T, Yata Y, Miyajima K, Hara S, Iwatani K, et al.
World J Urol
. 2024 Mar;
42(1):147.
PMID: 38478082
Objective: We aimed to assess the impact of the timing of urinary drainage on clinical outcomes in patients with obstructive pyelonephritis (OPN) associated with upper urinary tract (UUT) stones. Methods:...
10.
Shimomura T, Mori K, Yasue K, Matsukawa A, Fukuokaya W, Yanagisawa T, et al.
Int J Clin Oncol
. 2023 Dec;
29(2):213-221.
PMID: 38103156
Purpose: The androgen receptor axis-targeted (ARAT) agents abiraterone and enzalutamide have been introduced against castration-resistant prostate cancer (CRPC). However, determining which of these agents should be used first is a...